<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457938</url>
  </required_header>
  <id_info>
    <org_study_id>RO1-074959</org_study_id>
    <secondary_id>DK074959</secondary_id>
    <nct_id>NCT00457938</nct_id>
  </id_info>
  <brief_title>Novel Therapies for Metabolic Complications of Lipodystrophies</brief_title>
  <official_title>Novel Therapies for Metabolic Complications in Patients With Lipodystrophies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lipodystrophies represent a therapeutic challenge with regards to the management of the&#xD;
      diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present&#xD;
      in conjunction with significant adipose tissue loss. The purpose of the study and it's four&#xD;
      subprojects is to examine the safety and efficacy of various novel interventions designed to&#xD;
      improve or resolve the fatty liver, hypertriglyceridemia, and insulin resistance or diabetes&#xD;
      that is seen in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose novel therapeutic approaches for the management of metabolic complications in&#xD;
      patients with lipodystrophies. The four interventions to be tested are:&#xD;
&#xD;
      Hypothesis 1: An extremely low fat diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Project specific: improvement in serum triglycerides, insulin resistance, liver triglyceride content, liver volume, Hgb A1c,</measure>
    <time_frame>6 to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Diabetes</condition>
  <condition>Hepatic Steatosis</condition>
  <arm_group>
    <arm_group_label>Low fat diet is the &quot;drug&quot;</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diet 10% fat versus 35% fat</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low-fat diet ( Still recruiting )</intervention_name>
    <description>This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.</description>
    <arm_group_label>Low fat diet is the &quot;drug&quot;</arm_group_label>
    <other_name>Low fat versus extremely low fat Diet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>10 % versus 35 % fat in diet</description>
    <arm_group_label>Low fat diet is the &quot;drug&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion criteria:&#xD;
&#xD;
          -  Patients with lipodystrophies as diagnosed by clinical criteria&#xD;
&#xD;
          -  Any one of the following:&#xD;
&#xD;
               -  Diabetes mellitus, or&#xD;
&#xD;
               -  Fasting serum triglycerides greater than 200 mg/dL, or&#xD;
&#xD;
               -  Fasting serum insulin greater than 30 U/mL, or&#xD;
&#xD;
               -  Hepatic steatosis ( greater than 5.6% hepatic triglyceride content) as&#xD;
                  demonstrated by 1H MRS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known liver disease due to causes other than non-alcoholic steatohepatitis:&#xD;
&#xD;
          -  Current alcohol abuse (more than 7 drinks or 210 g per wk for women and more than 14&#xD;
             drinks or 420 g per wk for men).&#xD;
&#xD;
          -  Positive serological markers of hepatitis B and C.&#xD;
&#xD;
          -  Autoimmune hepatitis, autoimmune cholestatic liver disorders, Wilson disease and&#xD;
             Alpha-1-antitrypsin deficiency as indicated by clinical and laboratory tests.&#xD;
&#xD;
          -  Drug-induced liver disease&#xD;
&#xD;
          -  Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml&#xD;
             and/or liver mass on imaging study suggestive of liver cancer.&#xD;
&#xD;
          -  Decompensated liver disease as evidenced by clinical features of hepatic failure&#xD;
             (variceal bleeding, ascites, hepatic encephalopathy etc.) and laboratory&#xD;
             investigations (prolonged prothrombin time, hypoalbuminemia, presence of esophageal&#xD;
             varices etc.)&#xD;
&#xD;
          -  Use of the drugs which can potentially decrease hepatic steatosis during previous 3&#xD;
             months; high-dose vitamin E, betaine, acetylcysteine, choline and probucol.&#xD;
&#xD;
          -  Significant systemic or major illnesses other than liver disease (congestive heart&#xD;
             failure, unstable angina, cerebrovascular disease, respiratory failure, renal failure&#xD;
             [serum creatinine more then 2 mg/dL], acute pancreatitis, organ transplantation,&#xD;
             serious psychiatric disease, and malignancy) that could interfere with the trial and&#xD;
             adequate follow up.&#xD;
&#xD;
          -  Acute medical illnesses precluding participation in the studies.&#xD;
&#xD;
          -  Known HIV infected patient.&#xD;
&#xD;
          -  Current substance abuse.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Hematocrit of less than 30%.&#xD;
&#xD;
          -  History of weight loss ( more than 10%) or use of weight loss drugs such as&#xD;
             sibutramine or orlistat in the last 3 months.&#xD;
&#xD;
        Each subproject has additional specific inclusion and exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2007</study_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Abhimanyu Garg</investigator_full_name>
    <investigator_title>Chairman, Division Nutrition and Metabolic Diseases, Professor Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>lipodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

